Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vitamin B12 and folic acid is an investigational combination therapy developed by the Washington University School of Medicine to mitigate the risk of perioperative cardiac events, specifically myocardial ischemia. This intervention was studied in the VINO (Vitamins in Nitrous Oxide) trial, targeting patients with MTHFR gene variants (C677T or A1298C) undergoing noncardiac surgery with nitrous oxide anesthesia. The biological rationale is that nitrous oxide causes an acute increase in plasma homocysteine by irreversibly inactivating vitamin B12, which serves as a cofactor for methionine synthase. This acute hyperhomocysteinemia is associated with an increased risk of perioperative myocardial infarction. The treatment involves intravenous administration of 1 mg vitamin B12 and 5 mg folic acid to maintain the methionine cycle and prevent homocysteine accumulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vitamin b12 + folic acid.